Last --
Change Today 0.00 / 0.00%
Volume 0.0
530125 On Other Exchanges
Symbol
Exchange
530125 is not on other exchanges.
All times are local (Market data is delayed by at least 15 minutes).

samrat pharmachem ltd (530125) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
0.0
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SAMRAT PHARMACHEM LTD (530125)

Related News

No related news articles were found.

samrat pharmachem ltd (530125) Related Businessweek News

No Related Businessweek News Found

samrat pharmachem ltd (530125) Details

Samrat Pharmachem Limited manufactures, exports, imports, and sells pharmaceutical chemicals in India. It primarily sells iodine and bromine salts. Its products include calcium iodate monohydrate, copper iodide, hydriodic acid, iodine, iodine monochloride, iodoethane, iodomethane, potassium bromide, potassium iodate, potassium iodide, potassium metaperiodate, sodium iodate, sodium iodide, sodium metaperiodate, and trimethyl sulfoxoniumiodide. The company’s finished products are primarily used in various industries, such as pharmaceuticals, chemicals, food, fertilizer, and salt. Samrat Pharmachem Limited also exports its products to the United States, Europe, and Japan. The company was incorporated in 1992 and is based in Mumbai, India.

Founded in 1992

samrat pharmachem ltd (530125) Top Compensated Officers

Chairman, Managing Director and Chief Executi...
Total Annual Compensation: 1.5M
Executive Director of Finance and Executive D...
Total Annual Compensation: 1.4M
Compensation as of Fiscal Year 2013.

samrat pharmachem ltd (530125) Key Developments

Samrat Pharmachem Ltd. Reports Unaudited Standalone Earnings Results for the First Quarter Ended June 30, 2014

Samrat Pharmachem Ltd. reported unaudited standalone earnings results for the first quarter ended June 30, 2014. For the quarter, the company reported net income from sales/services was INR 141.384 million compared to INR 184.335 million a year ago. Profit from operations before other income, interest and exceptional items was INR 4.965 million compared to loss of INR 1.432 million a year ago. Profit from ordinary activities before tax of INR 4.041 million compared to loss of INR 3.307 million a year ago. Net profit was INR 2.393 million or INR 0.77 per basic and diluted share compared to net loss of INR 3.420 million or INR 1.11 per basic and diluted share a year ago.

Samrat Pharmachem Ltd, Board Meeting, Aug 14, 2014

Samrat Pharmachem Ltd, Board Meeting, Aug 14, 2014. Agenda: To consider unaudited standalone earnings results for the first quarter ended June 30, 2014.

Samrat Pharmachem Ltd Reports Unaudited Standalone Earnings Results for the Fourth Quarter and Audited Standalone Earnings Results for the Full Year Ended March 31, 2014

Samrat Pharmachem Ltd. reported unaudited standalone earnings results for the fourth quarter and audited standalone earnings results for the full year ended March 31, 2014. For the quarter, the company reported total income of INR 122.092 million compared to INR 172.709 million a year ago. Profit from operations before other income, interest and exceptional items were INR 4.277 million compared to loss from operations before other income, interest and exceptional items of INR 0.523 million a year ago. Profit from ordinary activates before tax was INR 3.994 million compared to INR 0.082 million a year ago. Net profit was INR 3.488 million or INR 1.13 per basic and diluted share before and after extraordinary items compared to net loss of INR 0.013 million or INR 0.00 per basic and diluted share before and after extraordinary items a year ago. For the year, the company reported total income of INR 654.268 million compared to INR 707.869 million a year ago. Profit from operations before other income, interest and exceptional items was INR 9.481 million compared to INR 12.712 million a year ago. Profit from ordinary activates before tax was INR 4.073 million compared to INR 5.817 million a year ago. Net profit was INR 2.417 million or INR 0.78 per basic and diluted share before and after extraordinary items compared to INR 4.004 million or INR 1.30 per basic and diluted share before and after extraordinary items a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SMPM:IN 26.00 INR -1.10

530125 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 530125.
View Industry Companies
 

Industry Analysis

530125

Industry Average

Valuation 530125 Industry Range
Price/Earnings 10.2x
Price/Sales 0.1x
Price/Book 0.6x
Price/Cash Flow 7.2x
TEV/Sales 0.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SAMRAT PHARMACHEM LTD, please visit www.samratpharmachem.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.